Janssen Research & Development, LLC has formed two new research agreements established through its Disease Interception Accelerator (DIA), a research unit focused on the prediction and preemption of diseases. Research alliances with Boston University School of Medicine (BUSM), aimed at identifying disease pathways associated with chronic obstructive pulmonary disease (COPD), and the Agency for Science, Technology and Research (A*STAR) in Singapore, focused on the identification of biomarkers in Gestational Diabetes Mellitus (GDM), mark the most recent of 24 total collaborations the DIA has initiated since its inception in February 2015. Through internal Janssen expertise and global partnerships, DIA scientists seek to integrate innovative science, novel therapeutics, precision diagnostics and new business models to address susceptibility to disease, and create solutions to intervene earlier and inhibit progression to disease.

In addition to GDM and COPD, the DIA has established ventures in Type 1 diabetes, presbyopia/cataracts, oral cavity & oropharyngeal cancer/cervical cancer and perinatal depression. Each venture has been selected based upon high unmet need, Janssen expertise and understanding of emerging science, and the potential for broader cross-disease applications for scientific learnings. The DIA is harnessing science and technology, both internally and externally, through partnerships and ongoing exploration of new collaborations with Johnson & Johnson Innovation.

Source: Johnson & Johnson